Sorafenib tosylate
Indications and Usage Mechanisms of Action Clinical Research Adverse reactions- Product Name
- Sorafenib tosylate
- CAS No.
- 475207-59-1
- Chemical Name
- Sorafenib tosylate
- Synonyms
- CL050;Sorafenib &Sorafeni tosylate;SORAFENIB TOSYLATE;Sorafinib mesylate;Sorafenib (Nexavar);Sorafenib TsOH salt;Sorafenib 475207-59-1;Sorafenib tosylate-002;BAY 43-9006;BAY43-9006
- CBNumber
- CB92131200
- Molecular Formula
- C21H16ClF3N4O3.C7H8O3S
- Formula Weight
- 637.03
- MOL File
- 475207-59-1.mol
Sorafenib tosylate Property
- Melting point:
- 229-232°C
- storage temp.
- 2-8°C(protect from light)
- solubility
- Soluble in DMSO (up to 200 mg/ml) or in Ethanol (up to 3 mg/ml).
- form
- solid
- color
- Off-white
- Stability:
- Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 1 month.
- InChI
- InChI=1S/C21H16ClF3N4O3.C7H8O3S/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25;1-6-2-4-7(5-3-6)11(8,9)10/h2-11H,1H3,(H,26,30)(H2,28,29,31);2-5H,1H3,(H,8,9,10)
- InChIKey
- IVDHYUQIDRJSTI-UHFFFAOYSA-N
- SMILES
- S(C1C=CC(C)=CC=1)(O)(=O)=O.O(C1C=CC(NC(=O)NC2C=CC(Cl)=C(C(F)(F)F)C=2)=CC=1)C1=CC=NC(C(=O)NC)=C1
- CAS DataBase Reference
- 475207-59-1(CAS DataBase Reference)
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Danger
- Hazard statements
-
H362May cause harm to breast-fed children
H372Causes damage to organs through prolonged or repeated exposure
H410Very toxic to aquatic life with long lasting effects
- Precautionary statements
-
P201Obtain special instructions before use.
P202Do not handle until all safety precautions have been read and understood.
P260Do not breathe dust/fume/gas/mist/vapours/spray.
P263Avoid contact during pregnancy/while nursing.
P273Avoid release to the environment.
P308+P313IF exposed or concerned: Get medical advice/attention.
N-Bromosuccinimide Price
- Product number
- Y0002236
- Product name
- Sorafenib for peak identification
- Purity
- European Pharmacopoeia (EP) Reference Standard
- Packaging
- Y0002236
- Price
- $202
- Updated
- 2024/03/01
- Product number
- Y0002224
- Product name
- Sorafenib tosilate
- Purity
- CRS, European Pharmacopoeia (EP) Reference Standard
- Packaging
- Y0002224
- Price
- $202
- Updated
- 2024/03/01
- Product number
- SML2633
- Product name
- Sorafenib tosylate
- Purity
- ≥98% (HPLC)
- Packaging
- 50MG
- Price
- $48.2
- Updated
- 2024/03/01
- Product number
- S676845
- Product name
- SorafenibTosylate
- Packaging
- 100mg
- Price
- $45
- Updated
- 2021/12/16
- Product number
- 289038
- Product name
- Sorafenib tosylate
- Packaging
- 1g
- Price
- $440
- Updated
- 2021/12/16
Sorafenib tosylate Chemical Properties,Usage,Production
Indications and Usage
Sorafenib tosylate is a new type of multi-target antitumor drug, was developed by the German Bayer Pharmaceuticals, and displayed expansive antitumor activity in preclinical animal tests. Sorafenib tosylate is mainly used in advanced liver cancer treatment and is well tolerated.
Mechanisms of Action
Sorafenib tosylate can simultaneously affect tumor cells and tumor blood vessels. It has a double antitumor effect: it can block the cell signal transduction pathways mediated by RAF/MEK/ERK to directly inhibit tumor cell growth, while also inhibiting VEGF and platelet derived growth factors (PDGF) receptors to prevent the formation of new tumor blood vessels, thus indirectly inhibiting tumor cell growth.
Clinical Research
In a stage three randomized clinical study of American and European treatments for advanced kidney cancer, 903 cases advanced kidney patients who had experienced one unsuccessful systematic treatment (biological immunity or chemotherapy) were randomly split into two groups. One group received sorafenib tosylate, while the other received a placebo. Mid-term analysis found already 222 deaths and the objective efficacy of the two groups to be 10% and 2%, while 74% and 53% of patients had stabilized conditions. The sorafenib tosylate group’s survival period was longer than that of the placebo group, with the risk ratio as 0.72. However, this different does not have statistical significance, as this is only a mid-term analysis, and final analysis after treatment will yield the correct survival period comparison.
602 advanced liver cancer patients selected from the USA, Europe, Australia, and other countries and areas, who did not receive systematic treatment, were included in a study. Results showed that compared to the placebo, taking sorafenib tosylate could extend their total survival period of patients with late stage or primary liver cancer by about 44% and their extend disease progression period by about 73%.
Adverse reactions
Manageable diarrhea, rashes, fatigue, hand-foot syndrome, hypertension, alopecia, nausea, vomiting, and loss of appetite.
Description
Sorafenib (475207-59-1) was initially developed as a Raf kinase inhibitor, IC50 = 6 nM, but has been shown to inhibit many receptor tyrosine kinases including BRAF (IC50 = 22 nM); VEGFR-2 (IC50 = 90 nM); VEGFR-3 (IC50 = 20 nM); PDGFR-β (IC50 = 57 nM); Flt3 (IC50 = 58 nM); c-KIT (IC50 = 68 nM); FGFR-1 (IC50 = 580 nM).1?Paradoxically more potent in a cellular assay (IC50 = 20 nM) compared to an isolated enzyme assay (IC50 = 107 nM) for c-Fms.2?Inhibits activation of MAPK pathway and ERK phosphorylation.3?Induces caspase-independent apoptosis in melanoma cells.4?Sorafenib is a clinically useful anticancer agent.
Uses
Sorafenib Tosylate (Bay 43-9006, Nexavar) is a small molecular inhibitor of VEGFR, PDGFR, c-Raf and B-Raf with IC50s of 18 nM, 10 nM, 3 nM and 15 nM, respectively.
Definition
ChEBI: Sorafenib tosylate is an organosulfonate salt. It contains a sorafenib.
brand name
Nexavar (Bayer).
General Description
Sorafenib is available in 200-mg tablets for oral administrationand is used in the treatment of RCC and colon cancer.The agent is classified as a multikinase inhibitor because ofits action on numerous kinase enzymes including thePDGF-R, VEGF-R, Kit, and Raf. Sorafenib is 39% to 48% bioavailable and CYP3A4-mediated metabolism giveseight identified metabolites including the N-oxide, which isequally active with the parent. However, the majority of thedrug in plasma is present as the parent compound.Sorafenib is highly protein bound (99.5%). The drug iseliminated primarily in the feces (77%) with 19% appearingin the urine as glucuronides (UGT1A1) and has a eliminationhalf-life of 24 to 48 hours. The most commonly seentoxicity is skin rash that normally occurs within the first6 weeks of therapy. Other adverse effects include hypertension,fatigue, increased wound healing time, and increasedrisk of bleeding.
Clinical Use
Sorafenib is used to treat late-stage kidney cancer (advanced renal cell carcinoma), liver cancer (hepatocellular carcinoma) that cannot be treated by surgery, and differentiated thyroid cancer that has come back or spread to other parts of your body. Sorafenib is an antineoplastic (cancer) agent. It interferes with the growth of cancer cells, which are eventually destroyed by the body.
Side effects
The side effects of Sorafenib tosylate include Bleeding gums, blistering, peeling, redness, or swelling of the palms of the hands or bottoms of the feet, bloating of the abdomen or stomach, blood in the urine or stools, clay-colored stools, coughing up blood, difficulty with breathing or swallowing, increased menstrual flow or vaginal bleeding.
target
Raf-1
References
1) Wilhelm et al. (2004), BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis; Cancer Res., 64 7099 2) Guo et al. (2006), Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors; Mol. Cancer Ther., 5 1007 3) Wilhelm et al. (2003), The novel Raf inhibitor BAY 43-9006 blocks signaling and proliferation in BRAF mutant and wildtype melanoma and colorectal tumor cell lies; Proc. Am. Assoc. Cancer Res., 44 106609 4) Panka et al. (2006), The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells; Cancer Res., 66 1611
Sorafenib tosylate Preparation Products And Raw materials
Raw materials
Preparation Products
Sorafenib tosylate Suppliers
- Tel
- 0518-87108777 13585296001
- haizaofu@163.com
- Country
- China
- ProdList
- 42
- Advantage
- 58
- Tel
- 020-39119399 18927568969
- Fax
- 020-39119999
- isunpharm@qq.com
- Country
- China
- ProdList
- 4428
- Advantage
- 55
- Tel
- 0514-80939770 13773367191
- Fax
- 0514-82664689
- yzqyyykj@163.com
- Country
- China
- ProdList
- 240
- Advantage
- 55
- Tel
- 010-67267894 18611880885
- gianord@163.com
- Country
- China
- ProdList
- 32
- Advantage
- 58
- Tel
- 0531-88072380 0531-88116830 13791093792
- sales@bestcomm.cn
- Country
- China
- ProdList
- 34
- Advantage
- 58
- Tel
- 13585296001
- haizaofu@163.com
- Country
- China
- ProdList
- 40
- Advantage
- 58
- Tel
- 027-83989310 18627915365
- Fax
- 027-83989310
- 2658488909@qq.com
- Country
- China
- ProdList
- 1297
- Advantage
- 58
- Tel
- 15898960030
- tanxiaohui@fengjin-pharma.com
- Country
- China
- ProdList
- 20
- Advantage
- 58
- Tel
- +86-0576--88902229 +86-13968687450
- yuxin@yuxchem.com
- Country
- China
- ProdList
- 209
- Advantage
- 58
- Tel
- Fax
- 86-21-57758967
- sales@boylechem.com
- Country
- China
- ProdList
- 2922
- Advantage
- 55
View Lastest Price from Sorafenib tosylate manufacturers
- Product
- Sorafenib Tosylate 475207-59-1
- Price
- US $0.00-0.00/kg
- Min. Order
- 1kg
- Purity
- 99%，single impurity＜0.1
- Supply Ability
- 1 ton
- Release date
- 2023-12-26
- Product
- Sorafenib tosylate 475207-59-1
- Price
- US $0.00-0.00/Kg/Drum
- Min. Order
- 1KG
- Purity
- 99%min
- Supply Ability
- 500KGS
- Release date
- 2021-09-13
- Product
- Sorafenib Tosylate 475207-59-1
- Price
- US $0.00/g
- Min. Order
- 1g
- Purity
- 98% HPLC
- Supply Ability
- 1kg
- Release date
- 2023-08-02